Kiora Pharmaceuticals Inc (NASDAQ:KPRX) — Market Cap & Net Worth
Market Cap & Net Worth: Kiora Pharmaceuticals Inc (KPRX)
Kiora Pharmaceuticals Inc (NASDAQ:KPRX) has a market capitalization of $10.68 Million ($10.68 Million) as of June 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #26882 globally and #5512 in its home market, demonstrating a -0.77% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Kiora Pharmaceuticals Inc's stock price $2.57 by its total outstanding shares 4432440 (4.43 Million). Review KPRX total liabilities to assess the company's total debt and financial obligations.
Kiora Pharmaceuticals Inc Market Cap History: 2015 to 2026
Kiora Pharmaceuticals Inc's market capitalization history from 2015 to 2026. Data shows change from $65.58 Billion to $11.39 Million (-56.34% CAGR).
Index Memberships
Kiora Pharmaceuticals Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.42 Trillion | 0.00% | #771 of 976 |
|
NASDAQ Composite
IXIC
|
$40.74 Trillion | 0.00% | #2502 of 3165 |
Weight: Kiora Pharmaceuticals Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Kiora Pharmaceuticals Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Kiora Pharmaceuticals Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.91x
Kiora Pharmaceuticals Inc's market cap is 0.91 times its annual revenue
Latest Price to Earnings (P/E) Ratio
4.07x
Kiora Pharmaceuticals Inc's market cap is 4.07 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $39.01 Billion | $669.26K | -$13.34 Million | 58294.83x | N/A |
| 2017 | $25.61 Billion | $407.52K | -$13.22 Million | 62845.42x | N/A |
| 2018 | $11.13 Billion | $1.65 Million | -$10.81 Million | 6735.08x | N/A |
| 2019 | $15.99 Billion | $2.69 Million | -$7.10 Million | 5952.61x | N/A |
| 2020 | $7.87 Billion | $12.06K | -$6.86 Million | 652350.49x | N/A |
| 2021 | $2.41 Billion | $12.06K | -$13.77 Million | 199807.15x | N/A |
| 2024 | $14.63 Million | $16.00 Million | $3.59 Million | 0.91x | 4.07x |
Competitor Companies of KPRX by Market Capitalization
Companies near Kiora Pharmaceuticals Inc in the global market cap rankings as of June 18, 2026.
Key companies related to Kiora Pharmaceuticals Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #222 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #444 globally with a market cap of $62.63 Billion USD.
- UCB SA (BR:UCB): Ranked #549 globally with a market cap of $49.68 Billion USD ( €42.50 Billion EUR).
- Argen-X (BR:ARGX): Ranked #573 globally with a market cap of $47.14 Billion USD ( €40.32 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #222 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $458.99 |
| #444 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $62.63 Billion | $607.93 |
| #549 | UCB SA | BR:UCB | $49.68 Billion | €252.40 |
| #573 | Argen-X | BR:ARGX | $47.14 Billion | €780.20 |
Kiora Pharmaceuticals Inc Historical Marketcap From 2015 to 2026
Between 2015 and today, Kiora Pharmaceuticals Inc's market cap moved from $65.58 Billion to $ 11.39 Million, with a yearly change of -56.34%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $11.39 Million | +30.46% |
| 2025 | $8.73 Million | -40.30% |
| 2024 | $14.63 Million | -29.76% |
| 2023 | $20.82 Million | -84.78% |
| 2022 | $136.83 Million | -94.32% |
| 2021 | $2.41 Billion | -69.37% |
| 2020 | $7.87 Billion | -50.80% |
| 2019 | $15.99 Billion | +43.66% |
| 2018 | $11.13 Billion | -56.54% |
| 2017 | $25.61 Billion | -34.36% |
| 2016 | $39.01 Billion | -40.51% |
| 2015 | $65.58 Billion | -- |
End of Day Market Cap According to Different Sources
On Jun 18th, 2026 the market cap of Kiora Pharmaceuticals Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $10.68 Million USD |
| MoneyControl | $10.68 Million USD |
| MarketWatch | $10.68 Million USD |
| marketcap.company | $10.68 Million USD |
| Reuters | $10.68 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Kiora Pharmaceuticals Inc
Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, engages in the development and commercialization of therapies for the treatment of ophthalmic diseases. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 2 clinical trials for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. The company is also deve… Read more